Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
8.93
Dollar change
+0.53
Percentage change
6.31
%
IndexRUT P/E- EPS (ttm)-3.05 Insider Own12.10% Shs Outstand34.40M Perf Week2.88%
Market Cap310.76M Forward P/E- EPS next Y-3.10 Insider Trans-0.18% Shs Float30.59M Perf Month-0.67%
Income-116.80M PEG- EPS next Q-0.81 Inst Own90.67% Short Float10.78% Perf Quarter-63.80%
Sales0.00M P/S- EPS this Y-9.23% Inst Trans-1.64% Short Ratio2.65 Perf Half Y-46.53%
Book/sh4.27 P/B2.09 EPS next Y6.83% ROA-53.15% Short Interest3.30M Perf Year-49.97%
Cash/sh4.56 P/C1.96 EPS next 5Y- ROE-59.56% 52W Range6.86 - 27.35 Perf YTD-64.06%
Dividend Est.- P/FCF- EPS past 5Y-12.39% ROI-77.10% 52W High-67.35% Beta0.47
Dividend TTM- Quick Ratio7.41 Sales past 5Y-36.87% Gross Margin-243.23% 52W Low30.17% ATR (14)0.91
Dividend Ex-Date- Current Ratio7.41 EPS Y/Y TTM-18.00% Oper. Margin0.00% RSI (14)36.89 Volatility5.27% 6.98%
Employees131 Debt/Eq0.05 Sales Y/Y TTM-100.00% Profit Margin- Recom1.92 Target Price22.00
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q-25.08% Payout- Rel Volume0.31 Prev Close8.40
Sales Surprise- EPS Surprise6.90% Sales Q/Q- EarningsMar 07 BMO Avg Volume1.25M Price8.93
SMA203.99% SMA50-45.95% SMA200-50.52% Trades Volume635,425 Change6.31%
Date Action Analyst Rating Change Price Target Change
Feb-22-24Downgrade UBS Buy → Neutral $61 → $10
Feb-21-24Downgrade Leerink Partners Outperform → Market Perform $42 → $10
Feb-21-24Downgrade JP Morgan Overweight → Neutral $35 → $15
Feb-21-24Downgrade H.C. Wainwright Buy → Neutral
Feb-20-24Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-16-24Initiated Evercore ISI Outperform
Feb-15-24Initiated Wolfe Research Outperform $39
Sep-14-23Initiated Berenberg Buy $34
Aug-09-23Initiated Stifel Buy $40
Jun-15-23Initiated Barclays Overweight $35
Mar-22-24 05:39AM
Mar-07-24 02:52PM
08:36AM
08:00AM
Mar-05-24 04:30PM
04:03PM Loading…
Feb-20-24 04:03PM
11:22AM
07:58AM
07:39AM
07:30AM
07:17AM
Feb-13-24 08:00AM
Jan-31-24 08:00AM
Jan-02-24 08:00AM
Nov-27-23 08:00AM
07:41PM Loading…
Nov-14-23 07:41PM
Nov-13-23 08:00AM
Nov-03-23 12:00PM
Nov-01-23 04:05PM
Oct-18-23 09:00AM
Sep-27-23 09:24PM
Sep-14-23 09:44AM
Aug-30-23 04:05PM
Aug-16-23 09:55AM
Aug-11-23 08:00AM
Aug-09-23 10:26AM
Aug-08-23 06:03AM
Jun-07-23 08:00AM
May-25-23 05:00PM
May-11-23 08:00AM
08:00AM Loading…
May-03-23 08:00AM
Apr-26-23 04:19PM
Mar-29-23 08:00AM
Mar-21-23 08:50AM
Mar-14-23 08:00AM
Mar-02-23 10:00AM
Feb-28-23 08:00AM
Feb-27-23 09:55AM
Feb-23-23 08:50AM
Feb-22-23 06:31AM
Feb-16-23 04:02AM
Feb-10-23 09:55AM
Feb-07-23 08:00AM
Jan-31-23 05:43PM
Jan-25-23 08:50AM
Jan-03-23 08:00AM
Dec-30-22 09:55AM
Dec-17-22 08:56AM
Dec-08-22 06:30AM
Nov-30-22 07:05PM
Nov-22-22 08:46AM
Nov-17-22 09:38PM
04:24PM
09:55AM
Nov-12-22 07:42AM
Nov-10-22 09:15AM
08:00AM
Nov-09-22 08:00AM
Oct-12-22 07:50AM
Sep-28-22 08:00AM
Sep-23-22 12:00PM
09:55AM
Sep-15-22 06:17AM
Sep-01-22 09:55AM
Aug-31-22 08:00AM
Aug-16-22 09:55AM
Aug-11-22 09:15AM
08:00AM
Jul-10-22 09:37AM
Jun-20-22 09:25AM
May-25-22 03:01PM
08:00AM
May-23-22 08:00AM
May-11-22 09:15AM
08:00AM
May-09-22 05:15PM
May-05-22 09:25AM
May-04-22 08:00AM
Apr-11-22 08:29AM
Mar-28-22 08:00AM
Mar-10-22 08:00AM
Mar-01-22 11:05AM
Feb-24-22 10:35AM
Feb-09-22 08:00AM
Feb-08-22 01:38PM
Jan-04-22 08:00AM
Nov-29-21 03:04PM
Nov-10-21 06:05PM
04:05PM
Nov-09-21 04:01PM
Nov-08-21 03:00PM
08:00AM
Oct-29-21 09:33AM
Oct-25-21 04:10PM
Oct-18-21 08:00AM
Sep-30-21 09:15AM
Sep-23-21 11:15AM
Sep-20-21 08:00AM
08:00AM
Sep-10-21 04:59PM
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brockstedt Dirk G.CHIEF SCIENTIFIC OFFICERJan 05 '24Sale22.7889820,45627,820Jan 08 05:50 PM
Brockstedt Dirk G.Chief Scientific OfficerDec 29 '23Option Exercise6.188,00049,44027,070Jan 02 04:29 PM
HO WILLIAMChief Medical OfficerDec 21 '23Sale21.682,50054,20015,020Dec 22 02:31 PM
HO WILLIAMChief Medical OfficerNov 28 '23Sale13.721,50020,58017,520Nov 29 02:29 PM
HO WILLIAMChief Medical OfficerOct 03 '23Sale15.772,50039,42518,789Oct 04 06:29 PM
HO WILLIAMChief Medical OfficerAug 18 '23Sale18.922,50047,30021,289Aug 22 12:19 PM
HO WILLIAMChief Medical OfficerJul 28 '23Option Exercise12.004605,52023,789Aug 03 02:34 PM
HO WILLIAMChief Medical OfficerJun 23 '23Option Exercise12.0092011,04023,329Jun 27 12:14 PM
HO WILLIAMChief Medical OfficerApr 19 '23Sale18.885,00094,40020,992Apr 20 02:17 PM
HO WILLIAMChief Medical OfficerApr 13 '23Option Exercise12.004605,52022,381Apr 14 06:25 PM